Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Insecticides | 5 | 2023 | 135 | 3.750 |
Why?
|
| Anopheles | 6 | 2023 | 309 | 3.710 |
Why?
|
| Malaria | 4 | 2023 | 213 | 2.770 |
Why?
|
| Oils, Volatile | 4 | 2023 | 10 | 2.530 |
Why?
|
| Plasmodium falciparum | 17 | 2024 | 64 | 2.040 |
Why?
|
| Antimalarials | 15 | 2024 | 33 | 1.930 |
Why?
|
| Animals | 14 | 2023 | 1081 | 1.220 |
Why?
|
| Mosquito Vectors | 6 | 2023 | 111 | 1.130 |
Why?
|
| Plant Extracts | 9 | 2013 | 32 | 0.870 |
Why?
|
| Acetylcholinesterase | 4 | 2022 | 12 | 0.820 |
Why?
|
| Pyrethrins | 1 | 2023 | 72 | 0.810 |
Why?
|
| Antiprotozoal Agents | 5 | 2024 | 7 | 0.650 |
Why?
|
| Farnesol | 3 | 2023 | 6 | 0.640 |
Why?
|
| Antimicrobial Stewardship | 3 | 2023 | 14 | 0.570 |
Why?
|
| Drug Design | 3 | 2024 | 29 | 0.550 |
Why?
|
| Phytotherapy | 3 | 2010 | 6 | 0.450 |
Why?
|
| Parasitic Sensitivity Tests | 7 | 2024 | 13 | 0.450 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2022 | 4 | 0.420 |
Why?
|
| Mammals | 2 | 2022 | 11 | 0.410 |
Why?
|
| Pyrimidines | 2 | 2024 | 32 | 0.410 |
Why?
|
| Students, Medical | 2 | 2023 | 14 | 0.400 |
Why?
|
| Mosquito Control | 2 | 2023 | 98 | 0.390 |
Why?
|
| Quinolines | 3 | 2021 | 14 | 0.380 |
Why?
|
| Students, Health Occupations | 2 | 2021 | 2 | 0.370 |
Why?
|
| Humans | 21 | 2024 | 14537 | 0.360 |
Why?
|
| Diphosphonates | 2 | 2019 | 4 | 0.330 |
Why?
|
| Molecular Docking Simulation | 4 | 2024 | 38 | 0.310 |
Why?
|
| Malaria, Falciparum | 3 | 2019 | 39 | 0.290 |
Why?
|
| Menispermaceae | 1 | 2007 | 1 | 0.290 |
Why?
|
| Vitamin B 12 | 1 | 2007 | 4 | 0.280 |
Why?
|
| Structure-Activity Relationship | 9 | 2024 | 28 | 0.280 |
Why?
|
| Chloroquine | 4 | 2016 | 10 | 0.260 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2024 | 125 | 0.260 |
Why?
|
| Molecular Structure | 7 | 2024 | 32 | 0.260 |
Why?
|
| Entamoeba histolytica | 3 | 2016 | 3 | 0.240 |
Why?
|
| Piperazines | 2 | 2016 | 82 | 0.230 |
Why?
|
| Triazines | 2 | 2016 | 3 | 0.230 |
Why?
|
| Propoxur | 1 | 2023 | 9 | 0.220 |
Why?
|
| Life Cycle Stages | 1 | 2023 | 16 | 0.220 |
Why?
|
| Mixed Function Oxygenases | 1 | 2023 | 6 | 0.210 |
Why?
|
| Larva | 1 | 2023 | 42 | 0.210 |
Why?
|
| Iron Chelating Agents | 2 | 1993 | 7 | 0.210 |
Why?
|
| Terpenes | 1 | 2022 | 2 | 0.210 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2023 | 6 | 0.210 |
Why?
|
| Anti-Bacterial Agents | 5 | 2023 | 293 | 0.210 |
Why?
|
| Rosales | 1 | 2002 | 1 | 0.210 |
Why?
|
| Organophosphates | 1 | 2021 | 9 | 0.190 |
Why?
|
| Ligands | 1 | 2021 | 33 | 0.190 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2021 | 25 | 0.190 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 217 | 0.180 |
Why?
|
| Cell Survival | 5 | 2021 | 48 | 0.170 |
Why?
|
| Metabolic Syndrome | 1 | 2020 | 64 | 0.170 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2020 | 69 | 0.170 |
Why?
|
| Nanotubes, Carbon | 1 | 2019 | 9 | 0.160 |
Why?
|
| Anti-Infective Agents | 4 | 2013 | 57 | 0.160 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 62 | 0.160 |
Why?
|
| Carbon | 1 | 2019 | 5 | 0.160 |
Why?
|
| Nanospheres | 1 | 2019 | 13 | 0.160 |
Why?
|
| Medicine, African Traditional | 3 | 2013 | 25 | 0.150 |
Why?
|
| Schools, Medical | 3 | 2023 | 8 | 0.140 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 237 | 0.140 |
Why?
|
| Curriculum | 3 | 2023 | 27 | 0.140 |
Why?
|
| Protozoan Proteins | 2 | 2016 | 3 | 0.140 |
Why?
|
| Folic Acid Antagonists | 1 | 2016 | 2 | 0.140 |
Why?
|
| Diamines | 1 | 2016 | 2 | 0.140 |
Why?
|
| HEK293 Cells | 3 | 2024 | 39 | 0.130 |
Why?
|
| Hypertension | 1 | 2020 | 419 | 0.130 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2010 | 10 | 0.130 |
Why?
|
| Hemeproteins | 3 | 2013 | 3 | 0.120 |
Why?
|
| Cell Line, Tumor | 5 | 2019 | 71 | 0.120 |
Why?
|
| Bacteria | 3 | 2010 | 47 | 0.120 |
Why?
|
| Microbial Sensitivity Tests | 6 | 2013 | 198 | 0.120 |
Why?
|
| Plant Leaves | 3 | 2010 | 13 | 0.110 |
Why?
|
| Plants, Medicinal | 1 | 2013 | 7 | 0.110 |
Why?
|
| Inhibitory Concentration 50 | 3 | 2016 | 19 | 0.110 |
Why?
|
| Pigments, Biological | 1 | 1993 | 2 | 0.110 |
Why?
|
| Dihydropteroate Synthase | 1 | 2013 | 3 | 0.110 |
Why?
|
| Iron | 1 | 1993 | 32 | 0.110 |
Why?
|
| Female | 2 | 2023 | 9103 | 0.100 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2013 | 103 | 0.100 |
Why?
|
| Drug Resistance | 2 | 2013 | 35 | 0.100 |
Why?
|
| Chalcones | 1 | 2011 | 1 | 0.090 |
Why?
|
| Antidiarrheals | 1 | 2010 | 1 | 0.090 |
Why?
|
| Escherichia coli Infections | 1 | 2010 | 3 | 0.090 |
Why?
|
| Tetrazolium Salts | 2 | 2008 | 3 | 0.090 |
Why?
|
| Thiazoles | 2 | 2008 | 6 | 0.090 |
Why?
|
| Escherichia coli | 1 | 2010 | 30 | 0.090 |
Why?
|
| Araliaceae | 1 | 2010 | 1 | 0.090 |
Why?
|
| Diarrhea | 1 | 2010 | 76 | 0.080 |
Why?
|
| Cell Line | 2 | 2016 | 93 | 0.080 |
Why?
|
| Vitex | 1 | 2008 | 1 | 0.080 |
Why?
|
| Commiphora | 1 | 2008 | 1 | 0.080 |
Why?
|
| Malvaceae | 1 | 2008 | 1 | 0.080 |
Why?
|
| Porphyrins | 1 | 2008 | 1 | 0.080 |
Why?
|
| Semicarbazides | 1 | 2008 | 1 | 0.080 |
Why?
|
| Drug Synergism | 3 | 2013 | 20 | 0.080 |
Why?
|
| Antioxidants | 4 | 2008 | 26 | 0.070 |
Why?
|
| Plant Roots | 1 | 2007 | 3 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 1422 | 0.070 |
Why?
|
| Salvia | 1 | 2005 | 1 | 0.060 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2011 | 10 | 0.060 |
Why?
|
| Erythrocytes | 2 | 2016 | 11 | 0.060 |
Why?
|
| Kinetics | 2 | 2019 | 65 | 0.060 |
Why?
|
| Cinnamates | 1 | 2024 | 1 | 0.060 |
Why?
|
| South Africa | 6 | 2020 | 7596 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2008 | 17 | 0.060 |
Why?
|
| Quinine | 2 | 2013 | 3 | 0.050 |
Why?
|
| Diterpenes | 1 | 2002 | 1 | 0.050 |
Why?
|
| Plant Stems | 1 | 2002 | 1 | 0.050 |
Why?
|
| Lactones | 1 | 2002 | 2 | 0.050 |
Why?
|
| Kidney | 1 | 2002 | 46 | 0.050 |
Why?
|
| Drug Resistance, Microbial | 1 | 2021 | 26 | 0.050 |
Why?
|
| Purines | 1 | 2001 | 2 | 0.050 |
Why?
|
| Perception | 1 | 2021 | 42 | 0.050 |
Why?
|
| Learning | 1 | 2021 | 12 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2013 | 279 | 0.050 |
Why?
|
| Stereoisomerism | 2 | 2011 | 3 | 0.050 |
Why?
|
| Thermodynamics | 1 | 2021 | 19 | 0.050 |
Why?
|
| United States | 1 | 2021 | 132 | 0.050 |
Why?
|
| Preoperative Period | 1 | 2020 | 3 | 0.050 |
Why?
|
| Models, Molecular | 1 | 2021 | 84 | 0.050 |
Why?
|
| Adenine | 1 | 2001 | 91 | 0.050 |
Why?
|
| Review Literature as Topic | 1 | 2020 | 6 | 0.040 |
Why?
|
| Plant Bark | 2 | 2010 | 4 | 0.040 |
Why?
|
| Spiro Compounds | 1 | 2019 | 5 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2019 | 6 | 0.040 |
Why?
|
| Drug Liberation | 1 | 2019 | 52 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 262 | 0.040 |
Why?
|
| Drug Carriers | 1 | 2019 | 93 | 0.040 |
Why?
|
| Mass Screening | 1 | 2020 | 245 | 0.040 |
Why?
|
| Picrates | 2 | 2008 | 3 | 0.040 |
Why?
|
| Free Radical Scavengers | 2 | 2008 | 6 | 0.040 |
Why?
|
| Lipoxygenase Inhibitors | 2 | 2008 | 4 | 0.040 |
Why?
|
| Biphenyl Compounds | 2 | 2008 | 4 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2020 | 317 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2019 | 252 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2008 | 18 | 0.040 |
Why?
|
| Thioredoxin-Disulfide Reductase | 1 | 2016 | 1 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2016 | 22 | 0.030 |
Why?
|
| Binding Sites | 1 | 2016 | 43 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1192 | 0.030 |
Why?
|
| Aged | 1 | 2020 | 1740 | 0.030 |
Why?
|
| Deferoxamine | 1 | 1993 | 1 | 0.030 |
Why?
|
| 2,2'-Dipyridyl | 1 | 1993 | 1 | 0.030 |
Why?
|
| Extracellular Space | 1 | 1993 | 2 | 0.030 |
Why?
|
| Ferric Compounds | 1 | 1993 | 5 | 0.030 |
Why?
|
| Hemolysis | 1 | 2013 | 7 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2013 | 12 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2013 | 139 | 0.030 |
Why?
|
| Pyrimethamine | 1 | 1992 | 1 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 263 | 0.030 |
Why?
|
| Middle Aged | 1 | 2020 | 3601 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2011 | 45 | 0.020 |
Why?
|
| Rubiaceae | 1 | 2010 | 1 | 0.020 |
Why?
|
| Myrtaceae | 1 | 2010 | 1 | 0.020 |
Why?
|
| Anacardiaceae | 1 | 2010 | 1 | 0.020 |
Why?
|
| Medicine, Traditional | 1 | 2010 | 7 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2013 | 889 | 0.020 |
Why?
|
| Hypoxanthine | 1 | 2010 | 1 | 0.020 |
Why?
|
| Adult | 1 | 2020 | 5913 | 0.020 |
Why?
|
| Male | 1 | 2020 | 6754 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2008 | 5 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2008 | 6 | 0.020 |
Why?
|
| Yeasts | 1 | 2008 | 3 | 0.020 |
Why?
|
| Benzothiazoles | 1 | 2008 | 3 | 0.020 |
Why?
|
| Sulfonic Acids | 1 | 2008 | 3 | 0.020 |
Why?
|
| Fungi | 1 | 2008 | 4 | 0.020 |
Why?
|
| Solvents | 1 | 2008 | 15 | 0.020 |
Why?
|
| Amoeba | 1 | 2008 | 1 | 0.020 |
Why?
|
| Plasmodium | 1 | 2008 | 14 | 0.020 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2005 | 5 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2005 | 39 | 0.020 |
Why?
|
| Isopentenyladenosine | 1 | 2001 | 1 | 0.010 |
Why?
|
| Kinetin | 1 | 2001 | 1 | 0.010 |
Why?
|
| Phosphotransferases | 1 | 2001 | 1 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2001 | 6 | 0.010 |
Why?
|